Skip to main content


BARDA announces expanded partnership with Beckman Coulter to assess digital sepsis prediction solution for COVID-19 patients

 

BARDA Response

BARDA and Beckman Coulter, in collaboration with Dascena, Inc., are expanding a public-private partnership to support additional advanced research and development that will optimize a machine-learning-based sepsis prediction and detection algorithm to include assessing its use with COVID-19 patients.

Based on machine learning, the sepsis diagnostic builds on Beckman Coulter’s existing Early Sepsis Indicator (MDW) which received FDA 510K clearance in April 2019 and integration with Dascena’s predictive algorithm for sepsis to create a digital prediction algorithm with the goal to advance to FDA approval. The expanded partnership will now include an emphasis on the earlier prediction of viral-induced sepsis (that can arise from SARS-CoV-2 infection).

This COVID-19 specific study is part of BARDA’s Rapidly Deployable Capabilities program to identify and pilot near-term innovative solutions for COVID-19, leveraging the development of this digital prediction algorithm under BARDA’s Division of Research Innovation and Venture (DRIVe’s) Solving Sepsis Program.

This award is one component of BARDA’s rapidly expanding COVID-19 Medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

The following descriptions are provided by the company and does not indicate an endorsement by the federal government of the company or its products:

 

About Beckman Coulter
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe.

Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter is headquartered in Brea, Calif., and has more than 11,000 global associates working diligently to make the world a healthier place. For more information, visit www.beckmancoulter.com.

About Dascena
Dascena, Inc. is developing machine learning diagnostic algorithms to enable early disease intervention and improve care outcomes for patients. For more information, visit Dascena.com.

Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov